Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.

ABSTRACT: Drug-resistant pathogens have gained a foothold especially in the most vulnerable patient populations, hospitalized and immunocompromised individuals. Furthermore, extended-spectrum β-lactamase and carbapenemase-producing organisms are finding their way even into the community, with patients presenting to the hospital with established colonization and infection with resistant Enterobacteriaceae in particular. Recently, a novel antipseudomonal cephalosporin in combination with an established Class A β-lactamase inhibitor, ceftolozane/tazobactam has been approved by the FDA for use in the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Ceftolozane is a uniquely potent antipseudomonal cephalosporin because of its high affinity for the penicillin-b

SUBMITTER: Skalweit MJ 

PROVIDER: S-EPMC4461093 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature